MEK Inhibitor PD-0325901 in Patients With Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas
Conditions:   Plexiform Neurofibroma;   Neurofibromatosis Type 1 (NF1) Intervention:   Drug: PD-0325901 oral capsule Sponsor:   SpringWorks Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 24, 2019 Category: Research Source Type: clinical trials

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
KENILWORTH, N.J.--(BUSINESS WIRE) April 1, 2019 --AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 1, 2019 Category: Pharmaceuticals Source Type: clinical trials

Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
1 April 2019 AstraZeneca and Merck& Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 1, 2019 Category: Pharmaceuticals Source Type: clinical trials

Whole-body Vibration in Children With Neurofibromatosis Type 1
Conditions:   Neurofibromatosis Type 1;   Muscle Weakness Interventions:   Device: Whole-body vibration;   Other: Muscle strengthening exercises Sponsors:   Manchester University NHS Foundation Trust;   Manchester Metropolitan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2019 Category: Research Source Type: clinical trials

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Conditions:   Neurofibromatosis 1;   Neurofibroma;   Atypical Neurofibroma;   Atypical Neurofibromatosis;   Plexiform Neurofibroma;   Von Recklinghausen Disease Intervention:   Diagnostic Test: Whole Body MRI Sponsor:   Children's Research Institute Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2019 Category: Research Source Type: clinical trials

Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation
Condition:   Neurofibromatosis Type 1 Intervention:   Sponsor:   Medical University Innsbruck Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2018 Category: Research Source Type: clinical trials

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Condition:   Neurofibroma, Plexiform Intervention:   Drug: Imatinib Mesylate Sponsors:   Indiana University;   Food and Drug Administration (FDA) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2018 Category: Research Source Type: clinical trials